Biogen Inc.

Is Biogen publicly traded?
Yes. It trades on NASDAQ under ticker BIIB.

What is Biogen's biggest drug?
Spinraza and Tysabri remain leading revenue products as the MS franchise declines; growth is led by Skyclarys, Zurzuvae, and Leqembi.

Who is the CEO of Biogen?
Christopher Viehbacher, president and chief executive officer.

Does Biogen make Leqembi?
Yes. Biogen co-develops and co-markets Leqembi (lecanemab) with Eisai.

Walter Gilbert, Phillip Sharp, and colleagues founded Biogen in Geneva in 1978, among the first dedicated biotechnology companies, before consolidating in Cambridge.

Its MS franchise, anchored by Avonex, Tysabri, and Tecfidera, drove two decades of growth, while the 2016 Spinraza launch made it a leader in spinal muscular atrophy and the Reata acquisition in 2023 added Skyclarys.

The Alzheimer's program has defined its modern controversy: Aduhelm's contested 2021 approval and 2024 discontinuation gave way to Leqembi, the Eisai-partnered anti-amyloid that became the first therapy to show disease modification with cleaner data.

Aduhelm's accelerated 2021 FDA approval, contested efficacy data, and subsequent withdrawal from the market remains one of the most debated drug approvals in recent history and triggered congressional scrutiny and coverage reversals.